54
Participants
Start Date
December 31, 2001
Study Completion Date
January 31, 2003
Bay 59-8862
75 mg/m2 of BAY 59-8862 intravenously over one hour. Treatment will be repeated once every 3 weeks and tumor measurements will be made every 2 cycles till progression, unacceptable toxicity or consent withdrawal
Caen
Greenbelt
Montpellier
Düsseldorf
Muncie
Southfield
Münster
Milwaukee
Billings
St Louis
St Louis
Heidelberg
Tübingen
München
München
Salt Lake City
La Jolla
New Orleans
Baltimore
Detroit
New Brunswick
Calgary
Edmonton
Greater Sudbury
Rotterdam
Plymouth
Manchester
Cardiff
Sutton
Lead Sponsor
Bayer
INDUSTRY